Biosynth Carbosynth to offer Enzyme Development following Acquisition of EUCODIS Bioscience
Expanded biological products and custom services offer for Life Science customers.
Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today that it has signed an agreement to acquire EUCODIS Bioscience (“EUCODIS”), experts in engineering and developing enzymes for pharma, biotech and applied markets.
The two companies have worked together on innovation projects in enzyme development for a number of years, with Biosynth already stocking EUCODIS’ catalogue enzymes as part of its broad research product offering.
The acquisition will broaden Biosynth’s biological products and custom services offering, with the biocatalysis, enzyme and recombinant protein expertise of EUCODIS complementing the biological materials supplied by Biosynth to the in-vitro diagnostics industry via its Aalto Bio Reagents subsidiary. Biosynth’s expanded Biologics offering will include custom and catalogue enzymes, antibodies, antigens, plasma along with epitope mapping services.
As part of the Biosynth group, EUCODIS will continue to provide state of the art services with the added benefit that customers will now profit from the combined expertise of EUCODIS and Biosynth in enzymes and chemical syntheses to enable novel biocatalytic synthesis routes for small molecules.
Dr. Urs Spitz, CEO and President of Biosynth, said, “Biosynth has collaborated with EUCODIS for many years, working on innovative enzyme projects for our customers and perfectly complementing our extensive expertise in enzyme substrate chemistry. It makes absolute sense for EUCODIS to join us as a key part of our biological materials offering. We are delighted to be able to welcome the experienced and knowledgeable team we know so well into the Biosynth family.”
Dr. Jan Modregger, CEO of EUCODIS, added, “We are pleased to be joining Biosynth, a group with which we have enjoyed a longstanding relationship and which shares our science-led and customer focused philosophy. We are excited by the opportunity to grow even faster and to provide high performance enzymes and biocatalysis solutions to a global customer base.”
About Biosynth Carbosynth
Biosynth Carbosynth is a supplier of critical materials to the life science industry with global research, manufacturing and distribution facilities. It is the supplier of choice for many in the pharmaceutical and diagnostic sectors and manufactures and sources a vast range of chemical and biochemical products. The company specializes in carbohydrates, nucleosides, enzyme substrates, peptides, phospholipids, antimicrobials, APIs and natural products and has a full range of reagents for protein production and analysis. Headquartered in Staad, Switzerland, Biosynth Carbosynth is owned by KKR, Ampersand Capital Partners and management. Find out more about Biosynth Carbosynth at www.biosynth-carbosynth.com.
About EUCODIS
EUCODIS Bioscience delivers high-performance enzyme solutions for applications in pharma, biotech, fine chemicals, food & feed, as well as the cosmetics industries. With a portfolio of over 50 enzymes including innovative lipases, beta-lactamases, peroxidases and other enzymes, EUCODIS Bioscience has a proven track record of providing customised solutions. As an application-driven provider of tailored enzyme solutions, the company works closely with its customers to better understand and fulfill their individual biocatalyst needs. Founded in 2007, EUCODIS has its headquarters in Vienna, Austria. For further information please visit www.eucodis.com.
Media Contacts
Biosynth Carbosynth
Aimee Cossins
+44 7984 525560